Physician profile
Duc Q Pham
NPI 1689615221
$13,194.61
in general payments reported to CMS, 2019-2025
58 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,366 · 2020: $1,453 · 2021: $1,889 · 2022: $1,978 · 2023: $1,758 · 2024: $1,547 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.83 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,669.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,234.32 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,232.33 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $1,002.83 | 2019-2025 | |
| Medtronic, INC. | $799.93 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Novo Nordisk INC | $720.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $612.76 | 2019-2025 | |
| Abbvie INC. | $546.16 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $528.69 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $496.37 | 2019-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $325.07 | 2019-2021 | |
| Allergan, INC. | $293.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $289.38 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $274.13 | 2019-2025 | Farxiga |
| Antares Pharma, INC. | $228.53 | 2019-2025 | Xyosted, Tlando, Nocdurna |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.